Supportive therapy for atopic dermatitis in children and adults

Matushevskaia E.V.; Kotsareva O.D.; Matushevskaia Iu.I.; Svirshchevskaia E.V.

doi:https://doi.org/10.17116/klinderma201716414-20

Close metadata

Recommended articles:

Assessment of the serum interleukin 33 (IL-33) level in patients with atopic dermatitis. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):293-296

Genesis of emollients. Past, present, future. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):412-420

From atopy to infection — a clinical case of combined skin pathology. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):430-436

Clinical case of nevoid hyperkeratosis of the nipple-areola complex. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):537-540

Atopic dermatitis: the problem of adherence to emollients. Russian Journal of Clinical Dermatology and Venereology. 2025;(5):698-707

Issues of diagnosis and treatment of atopic dermatitis. Russian Journal of Clinical Dermatology and Venereology. 2025;(6):838-845

Assessment of psychological trauma in patients with atopic dermatitis. Russian Journal of Clinical Dermatology and Venereology. 2026;(1):47-52

Mechanisms of additivity of physiotherapeutic factors in complex therapy of polypous rhinosinusitis complicated by comorbidities. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(3):5-11

Efficacy and Safety of the Oral Anticoagulant DIMOLEGIN Compared to Enoxaparin Sodium for the Prevention of Venous Thromboembolism Following Major Joint Replacement Surgery (hip or knee arthroplasty): A Randomized, Double-Blind, Multicenter Trial. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):577-585

Alveolar ridge bone augmentation using gene-activated bone substitute: long-term clinical follow-up. Stomatology. 2025;(6-2):56-64

Abstract:

The review presents the results of international and Russian clinical studies on the efficacy and safety of topical calcineurin inhibitors (TCI) in the treatment of atopic dermatitis. The main mechanisms of action of TCI and their influence on the barrier function of the skin have been described. We demonstrated the advantages of a TCI tacrolimus in terms of its efficacy, safety, and possibility of inclusion in the maintenance therapy compared to other topical anti-inflammatory medications. Hydrophilic dosage form and pharmacoeconomic index, which improve treatment compliance, suggest that the new drug product is an optimal topical agent for treatment of severe and medium atopic dermatitis.

Keywords:

topical calcineurin inhibitors

tacrolimus

atopic dermatitis

topical therapy

clinical trial

Authors:

Matushevskaia E.V.

FGOU Institut povysheniia kvalifikatsii Federal'nogo mediko-biologicheskogo agentstva RF, Moskva

Kotsareva O.D.

FGBUN «Institut bioorganicheskoj himii im. akademikov M.M. Shemjakina i Ju.A. Ovchinnikova» RAN, Moskva, Rossija, 117997

Matushevskaia Iu.I.

OOO "Kliniki Chaĭka", 123317, Moskva, Rossiĭskaia Federatsiia

Svirshchevskaia E.V.

Institut bioorganicheskoĭ khimii im. M.M. Shemiakina i Iu.A. Ovchinnikova RAN, Moskva, 117997, Rossiĭskaia Federatsiia

Close metadata

References:

Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40(9):1249-1255.
Stucker F, Ackermann D. Immunosuppressive drugs — how they work, their side effects and interactions. Ther Umsch. 2011;68(12):679-686.
Chia BK, Tey HL. Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis. 2015 May-Jun;26(3):122-132.
Ortiz RA, Barnes KC. Genetics of allergic diseases. Immunol Allergy Clin North Am. 2015 Feb;35(1):19-44.
Peng W, Novak N. Recent developments in atopic dermatitis. Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):417-422.
Ong PY. New insights in the pathogenesis of atopic dermatitis. Pediatr Res. 2014;75(1-2):171-175.
Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792-799.
McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280-291.
Santini MP, Talora C, Seki T, Bolgan L, Dotto GP. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA. 2001;14:98(17):9575-9580.
Jensen JM, Weppner M, Dähnhardt-Pfeiffer S, Neumann C, Bräutigam M, Schwarz T, Fölster-Holst R, Proksch E. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial. Acta Derm Venereol. 2013; 93(5):515-519.
Danby SG, Chittock J, Brown K, Albenali LH, Cork MJ. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol. 2014;170(4):914-921.
Jiráková A, Rob F, Sečníková Z, Koblová K, Džambová M, Rajská L, Göpfertová D, Pellacani G, Malý M, Lotti T, Hercogová J. Topical corticosteroids but not calceneurin inhibitors induced atrophy after four weeks. J Biol Regul Homeost Agents. 2015; 29(3):701-706.
Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, Walter K, Proksch E, Fölster-Holst R. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. J Dtsch Dermatol Ges. 2013;11(5):437-443.
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS,Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349.
Nakahara T, Koga T, Fukagawa S, Uchi H, Furue M. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis. J Dermatol. 2004;31:524-528.
Hebert AA, Koo J, Fowler J, Berman B, Rosenberg C, Levitt J. Desoximetasone 0.25% and tacrolimus 0,1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis. 2006;78:357-363.
Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0,1% used concomitantly with tacrolimus ointment 0,1% in atopic dermatitis. Cutis. 2003;72:161-166.
Spergel JM, Boguniewicz M, Paller AS, Hebert AA, Gallagher PR, McCormick C, Parneix-Spake A, Hultsch T. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol. 2007;157(2):378-381.
Danby SG, Chittock J, Brown K, Albenali LH, Cork MJ. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol. 2014;170(4):914-921.
Jiráková A, Rob F, Sečníková Z, Koblová K, Džambová M, Rajská L, Göpfertová D, Pellacani G, Malý M, Lotti T, Hercogová J. Topical corticosteroids but not calceneurin inhibitors induced atrophy after four weeks. J Biol Regul Homeost Agents. 2015;29(3):701-706.
Jensen JM, Weppner M, Dähnhardt-Pfeiffer S, Neumann C, Bräutigam M, Schwarz T, Fölster-Holst R, Proksch E. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial. Acta Derm Venereol. 2013;93(5):515-519.
Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, Walter K, Proksch E, Fölster-Holst R. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. J Dtsch Dermatol Ges. 2013;11(5):437-443.
Aschoff R, Schmitt J, Knuschke P, Koch E, Bräutigam M, Meurer M. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10): 832-836.
Zuo WX, Li XY, Cai GY, Chen YQ. A randomized single-blind controlled clinical trial of tacrolimus mouth rinse on erosive oral lichen planus. Shanghai Kou Qiang Yi Xue. 2013;22(6):708-710.
Stifft F, Vanmolkot F, Scheffers I, van Bortel L, Neef C, Christiaans M. Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2014;78(5):996-1004.
Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, ButterfassBahloul T, Augustin M, Luger TA, Ständer S. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology. 2013;227(4):353-360.
Ucak H, Demir B, Cicek D, Dertlioglu SB, Akkurt ZM, Ucmak D, Halisdemir N. Efficacy of topical tacrolimus for the treatment of persistent pruritus ani in patients with atopic dermatitis. J Dermatolog Treat. 2013;24(6): 454-457.
Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;79(1): 65-72.
Klinicheskie rekomendatsii po diagnostike i lecheniyu kozhnykh i venericheskikh bolezney Rossiiskogo obshchestva dermatovenerologov i kosmetologov (RODVK), 2005-2012.(In Russ.).
Funaro D, Lovett A, Leroux N, Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0,05% versus topical tacrolimus 0,1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2014;71(1):84-91.
Müller GG, José NK, de Castro RS. Topical tacrolimus 0,03% as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study. Eye Contact Lens. 2014;40(2):79-83.
Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. tacrolimus 0,03% cream. Ann Parasitol. 2013;59(2):73-77.
Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, Lehmann P, Wons A, Reitmeir P, Ruland V, Luger TA, Ruzicka T. Efficacy of tacrolimus 0,1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65(1):54-64, 64.e1-e2.
Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, Taïeb A, Lacour JP, Passeron T. Maintenance therapy of adult vitiligo with 0,1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135(4):970-974.
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of ato-pic dermatitis: Metaanalysis of randomised controlled trials. BMJ. 2005; 330:516.
Frohna JG. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: metaanalysis of randomised controlled trials. J Pediatr. 2005 Jul;147(1):126.
Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y. Efficacy of tacrolimus 0,03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0,005% ointment. Pediatr Allergy Immunol. 2010;21(2 Pt 1):321-329.
Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, Arcangeli F. Efficacy and safety of methylprednisolone aceponate ointment 0,1% compared to tacrolimus 0,03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184-189.
Rahman MF, Nandi AK, Kabir S, Kamal M, Basher MS, Banu LA. Topical Tacrolimus versus hydrocortisone on atopic dermatitis in paediatric patients: a randomized controlled trial. Mymensingh Med J. 2015;24(3):457-463.
Reitamo S, Luger TA, Steinhoff M. Textbook of atopic dermatitis. Informa Health Care. 2008;569.
Sokolovskiy EV, Monakhov KN, Dombrovskaya DK. The possibility to control skin condition in patients with chronic skin diseases using topical medications. Vestn Dermatol Venerol. 2011;3:4-21. (In Russ.).
Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M; European Tacrolimus Ointment Study Group. Proactive treatment of atopic dermatitis in adults with 0,1% tacrolimus ointment. Allergy. 2008;63(7):742-750.
Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T; European Tacrolimus Ointment Study Group. Proactive disease management with 0,03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159(6):1348-1356.
Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. J Dtsch Dermatol Ges. 2008;6(7):548-553.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606.
Zuberbier T, Heinzerling L, Bieber T, Schauer U, Klebs S, Bräutigam M. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology. 2007;215(4):325-330.
Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M; European Tacrolimus Ointment Study Group. Proactive treatment of atopic dermatitis in adults with 0,1% tacrolimus ointment. Allergy. 2008;63(7):742-750.
Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T; European Tacrolimus Ointment Study Group. Proactive disease management with 0,03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008; 159(6):1348-1356.
Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL; US. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis:a new paradigm for use; Pediatrics. 2008;122(6):e1210-e1218.
Crissinger A, Nguyen NV. The use of topical calcineurin inhibitors in atopic dermatitis. The Open Dermatology Journal. 2014;8:12-17.